# AMLX — Amylyx Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AMLX  
**Sources:** 22  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-amlx-amylyx-pharmaceuticals-inc-catalysts-narrative-risk-6027

---

## Overview

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a Cambridge, Massachusetts biopharmaceutical company that is repositioning itself away from its ALS legacy (AMX0035/Relyvrio, withdrawn in North America in April 2024) toward a late-stage endocrine/metabolic company built around its lead asset avexitide for post-bariatric hypoglycemia (PBH) [[1]](https://seekingalpha.com/article/4933147-amylyx-pharmaceuticals-avexitide-defines-the-endocrine-rebuild), [[2]](https://www.insidermonkey.com/blog/amylyx-amlx-faces-a-binary-phase-3-test-can-avexitide-rebuild-the-company-1811610/), [[22]](https://en.wikipedia.org/wiki/Amylyx_Pharmaceuticals). The stock has experienced extreme volatility over the past several months, and near the reference date (Oct 2, 2026) it was trading around $27.79, well off a 52-week high of ~$41.14, with a market capitalization of roughly $3.1 billion [[20]](https://www.marketbeat.com/stocks/NASDAQ/AMLX/).

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-amlx-amylyx-pharmaceuticals-inc-catalysts-narrative-risk-6027 (free to sign up)._